We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04182789
Previous Study | Return to List | Next Study

KN035 in Patients With Advanced Multiple Primary Tumors (CPOG035-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04182789
Recruitment Status : Unknown
Verified November 2019 by Haiyan Yang, RenJi Hospital.
Recruitment status was:  Recruiting
First Posted : December 2, 2019
Last Update Posted : December 2, 2019
Information provided by (Responsible Party):
Haiyan Yang, RenJi Hospital

Brief Summary:
This study is a prospective, single arm, single center exploratory clinical research, to evaluate KN035 late treatment in patients with Multiple Primary tumors (MPC, Multiple Primary working) clinical benefit.In the study, all subjects meeting the criteria for inclusion will be enrolled in the KN035 treatment group, and patients cannot receive any other anti-tumor treatment during the study period.The primary endpoint of the study was defined as patients who could be assessed by imaging, and the optimal Objective Response Rate (ORR) based on RECIST 1.1 standard, while the secondary endpoint was safety (nci-ctcae 4.0), DCR (Disease Control Rate), DoR (Duration of Response), progression-free survival (PFS),1) Overall Survival and Overall Survival;The end point of the exploratory study was the correlation between different molecular types and the efficacy of immunotherapy.

Condition or disease Intervention/treatment Phase
Multiple Primary Neoplasm Drug: KN035 Phase 2

Detailed Description:

Patients diagnosed with advanced MPC in the study should be enrolled as:

Histopathological diagnosis of multiple primary tumors, and is currently suffering from advanced colorectal cancer;Except for bowel cancer, no anti-tumor treatment is needed for other tumors during screening.

The maximum time interval between screening and treatment was 2 weeks (±7 days).Efficacy and safety were evaluated at 4 weeks (±7 days), 8 weeks (±7 days) after treatment, and every 8 weeks (±7 days) thereafter.Once a subject develops disease progression (based on investigator evaluation or imaging evidence), the subject should discontinue the study.Cessation of treatment for any reason should be followed by a study end visit within 4 weeks (±7) days after the last study administration to collect information on all possible adverse events and drug combinations.Drug - related or possibly related adverse events should be followed up until they are stable or resolved.SAE should be documented within 30 days of study cessation.KN035 can be used for up to 2 years.

When desease progression is suspected, researchers are allowed to reconfirm disease progression after 4 weeks using irRECIST criteria.During the confirmation of disease progression, if the investigator decides that the subject should continue to receive KN035 treatment, the following criteria must be met:

The researchers assessed whether the subjects had benefited or were likely to continue to benefit:

①Subjects can tolerate study drug therapy;

②There were no medical events (e.g., central nervous system metastases) in which tumor progression was rapid or urgent intervention was required.

Study endpoint analysis will be performed when the last patient is followed for 24 weeks or disease progression or death is observed.If there is still no disease progression or intolerable adverse reactions, the patient will continue to receive KN035 treatment until the disease progression, death, occurrence of intolerable adverse reactions or treatment for 1 year (the researcher will give follow-up treatment recommendations according to the specific situation, if the original treatment is continued, the patient can still receive KN035 treatment for free).Treatment options after disease progression will be implemented at the discretion of the investigator.After the end of the study visit, subjects will enter the post-study follow-up period to collect survival data OS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Single Arm Exploratory Clinical Research on the Efficacy and Safety of KN035 in Patients With Advanced Multiple Primary Tumors
Actual Study Start Date : March 26, 2019
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : August 2021

Arm Intervention/treatment
Experimental: KN035
KN035150mg,once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
Drug: KN035
KN035150mg,once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.

Primary Outcome Measures :
  1. ORR [ Time Frame: through study completion, an average of 1 year ]
    Objective Response Rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, aged 18 or above, 70 or below;
  2. Patients with multiple primary tumors (currently suffering from colorectal cancer) diagnosed by histopathology (diagnostic criteria: ①the diagnosis of each malignant tumor must be confirmed by tissue/cytology;

    ②the pathological diagnosis of each malignant tumor has its unique pathological morphological support, different from other diagnoses;

    ③each malignant tumor diagnosis of the original site occurred in different parts, any two diagnosis is not mutually continuous;

    ④one of the diagnosis must be primary bowel cancer; (except for bowel cancer, other tumors do not need anti-tumor treatment);

  3. Currently suffering from intestinal cancer and distant metastasis;
  4. Received second-line or above treatment before, and the disease progress was determined by imaging; Or unable to tolerate any line treatment (including adjuvant or first-line treatment, etc., first-line treatment requires oxaliplatin, irinotecan and fluorouracil drugs);
  5. At least one measurable lesion (RECIST 1.1);
  6. ECOG score 0 or 1;
  7. Expected survival≥12 weeks;
  8. Adequate organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 1 week prior to the first study) :

(1) blood routine examination: leukocyte ≥3.0 ×109/L, neutrophil ≥1.5 ×109/L, platelet ≥75 ×109/L, hemoglobin ≥ 9.0g /dL; (2) liver function: total bilirubin ≤1.5 ×ULN; ALT/AST≤2.5 ×ULN without liver metastasis; ALT/AST≤5 ×ULN in liver metastasis; (3) renal function: serum creatinine≥1.5 x ULN; (4) adequate cardiac function, left ventricular ejection fraction (LVEF) > 50% of 2-d echocardiography.

9. Fully understand the study and sign informed consent voluntarily; 10. Women of reproductive age who have had a negative pregnancy test are willing to take effective contraceptive measures during the study period and within 90 days after the last dose of medication.

Exclusion Criteria:

  1. Participate in clinical trials of other research drugs within 30 days before the first study drug treatment;Or received anti-tumor therapy within 2 weeks, including but not limited to chemotherapy, radiotherapy, targeted therapy, or anti-tumor therapy, the toxic response has not returned to the level 0 or level 1 (hair loss, ≤grade 2 peripheral neurotoxicity induced by chemotherapy can be included);
  2. Previous immune checkpoint drug therapy;
  3. Major surgery (except biopsy) or incomplete incision healing was performed within 4 weeks before the first study of drug therapy;
  4. Ascites requiring drainage or diuretic treatment or hydrothorax or pericardial effusion requiring drainage and/or symptoms of shortness of breath within 2 weeks before the first study;
  5. Active brain metastasis or spinal cord compression;For patients with brain metastasis who had received previous treatment, if the clinical conditions were stable within 4 weeks before the first study of drug treatment and the imaging evidence did not show the disease progression, and if they did not need corticosteroid treatment within 2 weeks before the first treatment, they could be considered to be enrolled.
  6. Active, known or suspected autoimmune diseases (patients with vitiligo who do not require systematic treatment within 2 years before the first study of drug therapy are allowed to be enrolled;Patients with hypothyroidism requiring only thyroid hormone replacement therapy, type 1 diabetes requiring only insulin replacement therapy, and patients with pituitary inflammation and adrenocortical dysfunction requiring only physiological hormone replacement therapy can be enrolled);
  7. Hiv-infected patients;
  8. An active bacterial or fungal infection requiring systematic treatment 14 days before the first study drug treatment;
  9. Previous history of interstitial lung disease, drug-induced interstitial lung disease, radioactive pneumonia, symptomatic interstitial lung disease, or any evidence of active pneumonia on chest CT scan within 4 weeks prior to initial study drug treatment;
  10. HBV DNA≥2000 IU/ml (or 104 copies /ml) during screening period in patients with hepatitis b; Note: for enrolled subjects with anti-hbc (+)/HBsAg (+)/HBV DNA<2000 IU/ml or anti-hbc (+)/HBsAg (-)/HBV DNA<2000 IU/ml, antiviral therapy must be provided at the same time during the trial, either with the original drug or entecavir.For enrolled HCV rna-positive subjects, it was up to the investigator to decide whether to also receive antiviral therapy.
  11. Clinically significant cardiovascular diseases, including but not limited to acute myocardial infarction, severe/unstable angina, cerebrovascular accident or transient ischemic attack, and congestive heart failure within the first 6 months of enrollment (New York heart association grade ≥ 2);Arrhythmias that require other antiarrhythmic drugs in addition to beta blockers or digoxin;Repeated electrocardiogram (ecg) detection of QTcF interval of >450 milliseconds (ms);Hypertension not well controlled by antihypertensive drugs (systolic blood pressure >150mmHg, diastolic blood pressure >100mmHg);
  12. Abnormal thyroid function exists, and the use of drugs cannot maintain thyroid function in the normal range;
  13. Clinically significant abnormal serum electrolyte level;
  14. Immunosuppressive drugs were used within 2 weeks before the first study drug treatment, excluding local or systemic glucocorticoids not exceeding 10 mg/ d prednisone or other glucocorticoids of equivalent dose;
  15. Live vaccine should be administered within 4 weeks before or during the first study period of drug therapy.
  16. Has a history of severe allergic reactions to chimeric or human antibodies or fusion proteins or is known to be allergic to biological products or any component of KN035 produced from Chinese hamster ovary cells;
  17. Pregnant or lactating women;
  18. Fertility but unwillingness to accept effective contraception;
  19. Any other disease, metabolic disorder or abnormal laboratory test, the researchers have reason to suspect that the patient is not fit to be treated with the study drug, or will affect the interpretation of the study results, or put the patient at high risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04182789

Layout table for location contacts
Contact: Haiyan Yang, doctor 8621-58782345 ext 5559 13916708215@163.com

Layout table for location information
China, Shanghai
RenJi Hospital Recruiting
Shanghai, Shanghai, China, 200027
Contact: Haiyan Yang, doctor    8621-58752345 ext 5559    13916708215@163.com   
Sponsors and Collaborators
RenJi Hospital
Layout table for additonal information
Responsible Party: Haiyan Yang, ONCOLOGY DEPT., RenJi Hospital
ClinicalTrials.gov Identifier: NCT04182789    
Other Study ID Numbers: YHY
First Posted: December 2, 2019    Key Record Dates
Last Update Posted: December 2, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Multiple Primary